

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 DECEMBER 2013

ERRATA

(1) This Erratum corrects the entry for Olanzapine in the 1 December 2013 Schedule.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note was omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

(2) This Erratum corrects the entry for Tocilizumab in the 1 December 2013 Schedule.

The Notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 DECEMBER 2013—ERRATA

(3) This Erratum corrects the entry in the 1 December 2013 Schedule for raloxifene hydrochloride 60 mg tablet, 28.

The Schedule entry should appear as shown below. The brands *Evifyne* and *Raloxifene GH* have been deleted.

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
8363E NP	<p>RALOXIFENE <u>Authority required (STREAMLINED)</u> 4071 Established post-menopausal osteoporosis The Clinical criteria is: Patient must have fracture due to minimal trauma, AND the Clinical criteria is: Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition. The fracture must have been demonstrated radiologically and the year of plain x-ray or computed tomography (CT) scan or magnetic resonance imaging (MRI) scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Note Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, denosumab, raloxifene hydrochloride, strontium ranelate and zoledronic acid.</p>	1	5	..	58.08	36.10	Evista	LY